{"id":"W2795475769","doi":"10.1186/s12885-018-4275-z","title":"Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial","year":2018,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Genome British Columbia","funders":"Vlaamse regering; European Society for Medical Oncology; Fonds Wetenschappelijk Onderzoek; Janssen Pharmaceuticals; American Association for Cancer Research; Waalse Gewest; European Regional Development Fund; European Organisation for Research and Treatment of Cancer","keywords":"Medicine; Prostate cancer; Prostatectomy; Urology; Placebo; Clinical endpoint; Antiandrogen; Androgen deprivation therapy; Internal medicine; Androgen receptor; Oncology; Randomized controlled trial; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001936441,0.001515641,0.003399156,0.0005373397,0.0004865901,0.001122762,0.0008119254,0.002391796,0.005629461],"category_scores_gemma":[0.001459812,0.0005611698,0.001876136,0.0003925794,0.001244847,0.001124577,0.0004045148,0.002199647,0.0008791115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005297993,"about_ca_system_score_gemma":0.0009706167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004782754,"about_ca_topic_score_gemma":0.001085302,"domain_scores_codex":[0.9991626,0.0004556714,0.00004837646,0.0001643345,0.00007346495,0.00009565002],"domain_scores_gemma":[0.9991786,0.000210775,0.0002102041,0.00006887841,0.00005250192,0.0002789272],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9846602,0.004356325,0.0001712215,0.0006471204,0.0004143951,0.0000176623,0.00001779723,0.0001026643,0.001655924,0.00007326819,0.0003547219,0.007528811],"study_design_scores_gemma":[0.94712,0.05083115,0.0006170683,0.00005267385,0.0003469288,0.00002153945,0.00001078527,0.0001488465,0.0001941565,0.00008527969,0.0005590776,0.0000124545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9603732,0.02479886,0.001111177,0.001883883,0.001880205,0.004933849,0.001194381,0.0003092459,0.003515239],"genre_scores_gemma":[0.9651875,0.009192421,0.003686212,0.003333249,0.001676907,0.009385246,0.00127266,0.00004511451,0.006220629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005629461,"threshold_uncertainty_score":0.01883239,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02400971476274088,"score_gpt":0.3376450807353841,"score_spread":0.3136353659726432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}